The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.
Shaji Kumar
Consulting or Advisory Role - Abbvie (Inst); Abbvie (Inst); Adaptive Biotechnologies; Amgen (Inst); Bluebird Bio (Inst); Celgene (Inst); Genecentrix; Genentech/Roche (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Merck (Inst); Molecular Partners (Inst); Oncopeptides; Takeda (Inst)
Research Funding - Abbvie (Inst); CARsgen Therapeutics (Inst); Celgene (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); TeneoBio (Inst)
Susanna J. Jacobus
No Relationships to Disclose
Adam D. Cohen
Consulting or Advisory Role - Celgene; GlaxoSmithKline; Janssen Oncology; Kite, a Gilead company; Oncopeptides; Seattle Genetics; Takeda
Research Funding - Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patents related to CAR T cells and biomarkers of Cytokine Release Syndrome
Expert Testimony - Janssen Oncology
Travel, Accommodations, Expenses - Celgene; GlaxoSmithKline; Janssen Oncology; Janssen Oncology; Takeda
Matthias Weiss
No Relationships to Disclose
Natalie Scott Callander
Research Funding - Cellectar
Avina A. Singh
No Relationships to Disclose
Terri L. Parker
No Relationships to Disclose
Alex R. Menter
No Relationships to Disclose
Xuezhong Yang
No Relationships to Disclose
Benjamin Marshall Parsons
Consulting or Advisory Role - Amgen; Celgene
Speakers' Bureau - Amgen; Celgene
Pankaj Kumar
No Relationships to Disclose
Prashant Kapoor
Honoraria - Cellectar; GlaxoSmithKline (Inst); Karyopharm Therapeutics; Pharmacyclics; Sanofi (Inst)
Consulting or Advisory Role - Sanofi (Inst)
Speakers' Bureau - Clinical Care Options
Research Funding - Abbvie (Inst); Amgen (Inst); GlaxoSmithKline (Inst); Sanofi (Inst); Sorrento Therapeutics (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Axis Pharma; GlaxoSmithKline; Janssen; Sanofi; Takeda
Aaron Seth Rosenberg
Consulting or Advisory Role - Amgen; Karyopharm Therapeutics; Seattle Genetics
Speakers' Bureau - Janssen; Takeda
Research Funding - Amgen; Amgen (Inst)
Jeffrey A. Zonder
Consulting or Advisory Role - Alnylam; Amgen; Bristol-Myers Squibb; Caelum Biosciences; Celgene; Intellia Therapeutics; Janssen; Oncotherapeutics; Prothena; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst)
Edward Anthony Faber
Consulting or Advisory Role - Amgen; Celgene; Janssen; Juno Therapeutics; Kite/Gilead
Travel, Accommodations, Expenses - Amgen; Celgene; Janssen
Sagar Lonial
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen Oncology; Juno Therapeutics; Merck; Novartis; Takeda
Research Funding - Bristol-Myers Squibb; Celgene; Takeda
Paul G. Richardson
Consulting or Advisory Role - Celgene; Janssen; Jazz Pharmaceuticals; Karyopharm Therapeutics; Oncopeptides; Sanofi; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Oncopeptides (Inst); Takeda (Inst)
Robert Z. Orlowski
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Kite, a Gilead company; Sanofi; Takeda
Research Funding - Amgen; BioTheryX; Spectrum Pharmaceuticals
Lynne I. Wagner
Consulting or Advisory Role - Celgene
Travel, Accommodations, Expenses - Celgene
S. Vincent Rajkumar
No Relationships to Disclose